If the proposed rule is finalized, it will impose the regulatory controls and criminal sanctions of schedule IV on anyone who handles propofol and products containing the drug.
According to an ASA news release, “ASA hopes that the tighter controls and monitoring that accompany scheduling will reduce the potential for abuse, although we recognize that such action will not completely prevent all problems associated with the misuse of propofol.”
Comments on the proposed rule are due Dec. 27.
Read the ASA news release about the proposed propofol scheduling.
View the Federal Register notice about the proposed rule for propofol (pdf).
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
